Alzheimer's Disease
Conditions
Interventions
Observation Group (Rivastigmine Hydrogen Tartrate Tablets:NA
Control Group A (Donepezil Tablets):NA
Control Group B (Huperzine A Tablets):NA
Sponsors
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age >=50 years old, regardless of gender; 2. Meet the aforementioned diagnostic criteria for AD, with a confirmed mild to moderate disease course, and a Clinical Dementia Rating (CDR) score of 1–2 and a Mini-Mental State Examination (MMSE) score of 10–24 (matching the population indicated for mild to moderate AD with the three medications); 3. The treating physician deems it necessary to initiate cholinesterase inhibitor therapy, and the treatment goal aligns with improving symptoms of mild to moderate AD; 4. Informed consent obtained from the patient or their family, with a signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Concurrent severe diseases of vital organs (e.g., heart, liver, kidneys) or systemic illnesses. 2. Presence of other conditions that may cause dementia (such as central nervous system infections, Parkinson's disease, Lewy body dementia, brain tumors, thyroid disorders, etc.). 3. Concurrent neurological diseases other than AD (e.g., stroke, epilepsy). 4. History of alcohol abuse or substance abuse within 1 year prior to enrollment. 5. Use of cognitive impairment treatment drugs such as lecanemab within 2 months prior to enrollment. 6. Allergic to heavy tartrate carbidopa, donepezil, huperzine A, or any of their components, or having contraindications to the use of corresponding drugs (such as atrioventricular block for donepezil, and severe hepatic and renal insufficiency for huperzine A); 7. Having uncorrectable visual and auditory impairments that affect scale assessment; 8. Deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| psychiatric and behavioral symptoms;Cognitive status;Clinical chemistry and complete blood count (CBC);Activities of Daily Living; | — |
Countries
China
Contacts
Public ContactPing Luan
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Outcome results
None listed